Paul Wallace

Paul Wallace currently serves as Chief Business Officer at Constructive Bio, a company focusing on innovative genome synthesis technologies. Wallace has also held the position of Chairman and Non-Executive Director at Semarion since 2020, where the company develops micro-scale cell carriers for advanced cell-based assays. With extensive experience in the life sciences sector, Wallace has been an advisor and mentor to various companies and previously served as Chief Business Officer at Mission Therapeutics, targeting therapies for neurodegenerative and other diseases. Prior roles include executive positions at Medivir AB, Acambis plc, and Peptide Therapeutics plc, along with founding research initiatives at Eclagen Ltd. and leadership in recombinant antibody therapeutics at Scotgen Biopharmaceuticals. Educational credentials include a Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge and a first-class B.Sc. in Biochemistry from the University of St Andrews.